RE:RE:RE:Excellent news! Out first official exposure to ASCO world
StevenBirch wrote: That's what stuck out to me, previously they went to these symposiums and talked broadly about PDT or PDT as a way to treat NMIBC but now they are presenting TLT's results and analysis. For those wanting more exposure you got it.
ScienceFirst wrote: The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.
Great exposure at the perfect time....couldn't ask for more. Now, it will be interesting to see "how" the data is presented. I'm hoping emphasis will be placed not only on the wonderful durable response data as a whole (a total of 29+ patients, including Ph 1b), but also on what an optimized & currently recommended protocol can get you. That distinction would be worth noting & should be prefaced before the total data presentation imo...that's what I anticipate our good doctor/presenter will do. The importance of more "clinical" eyes on this tech cannot be overstated. Many/most of the ASCO meeting attendees will be clinicians in oncology & "not" be primarily research/lab-based docs....advantage TLT. Good luck.